{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:19:18Z","timestamp":1778897958031,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ajoc.2020.100687","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T19:37:22Z","timestamp":1585856242000},"page":"100687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations"],"prefix":"10.1016","volume":"18","author":[{"given":"Atul","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophaktra","family":"Chea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3495-7460","authenticated-orcid":false,"given":"Wataru","family":"Matsumiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Sohail","family":"Halim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7igdem","family":"Ya\u015far","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasir J.","family":"Sepah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana V.","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan Dong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajoc.2020.100687_bib1","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2146\/ajhp070342","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"65","author":"Hernandez-Pastor","year":"2008","journal-title":"Am J Health Syst Pharm: Offc J Am Soc Health Sys Pharama"},{"key":"10.1016\/j.ajoc.2020.100687_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1136\/pgmj.2006.052944","article-title":"Age-related macular degeneration and recent developments: new hope for old eyes?","volume":"83","author":"Morris","year":"2007","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ajoc.2020.100687_bib3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob health"},{"key":"10.1016\/j.ajoc.2020.100687_bib4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib6","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","article-title":"Brolucizumab: first approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ajoc.2020.100687_bib7","author":"American Society of Retina Specialists"},{"key":"10.1016\/j.ajoc.2020.100687_bib8","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib9","unstructured":"Dugel P.U. Expanded week 96 safety outcomes: analysis of pooled data from HAWK & HARRIER studies. Presented at the 2020 Meeting of the Macula Society, March 19 to 22, San Diego, California."},{"key":"10.1016\/j.ajoc.2020.100687_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib12","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1016\/j.ophtha.2016.08.040","article-title":"Twenty-four-month outcomes of the ranibizumab for edema of the macula in diabetes - protocol 3 with high dose (READ-3) study","volume":"123","author":"Sepah","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib13","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib14","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajoc.2020.100687_bib15","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.oret.2018.02.011","article-title":"Evaluating the impact of intravitreal aflibercept on diabetic retinopathy progression in the VIVID-DME and VISTA-DME studies","volume":"2","author":"Mitchell","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajoc.2020.100687_bib16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib17","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajoc.2020.100687_bib18","unstructured":"Data on File. Regeneron Pharmaceuticals, Inc. Tarrytown, NY 10591."},{"key":"10.1016\/j.ajoc.2020.100687_bib19","series-title":"Data on File. Internal Sales Data","year":"2020"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245199362030058X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S245199362030058X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:57:10Z","timestamp":1762527430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S245199362030058X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":19,"alternative-id":["S245199362030058X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100687","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100687"}}